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injection cost of $23.10, and office visit cost of $42.45. RESULTS: The annual 
average drug costs per patient were $4,590 (DA) and $5,244 (EA). Average drug 
costs for administrations were $92 (DA) and $277 (EA). Per member per year 
(PMPY) costs were $4,682 (DA) and $5,521(EA). The annual total costs per 
population (n=1,755) were $8,217,612 (DA) and $9,688,952 (EA). CONCLUSIONS: 
DA Q3W has the potential to provide cost savings over EA QW in terms of annual 
average drug cost per patient ($654 savings), per member per year ($839 savings), 
and total cost per population ($1,471,340 savings). DA Q3W may offer a cost 
advantage over EA QW as it allows for synchronizing of anemia management 
with ongoing cancer treatments, which may reduce required patient visits and 
blood tests.  
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BUDGET IMPACT ANALYSIS (BIA) OF CABAZITAXEL INTRODUCTION IN 
TREATMENT OF METASTATIC HORMONE-REFRACTORY PROSTATE CANCER 
(MHRPC) IN RUSSIAN FEDERATION  
Yagudina R1, Kulikov A1, Kogon L2 
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2FGBU NCESMP Ministry 
of Health Russia, Moscow, Moscow, Russia  
OBJECTIVES: The purpose of this study was to evaluate financial impact on 
Russian National Healthcare Service (RNHS) budget of the introduction of 
Cabazitaxel in second-line treatment of patients with mHRPC previously treated 
with a Docetaxel-containing regimen in first-line. METHODS: The numbers of 
mHRPC patients eligible for first-line and second-line treatment were estimated 
based on local demographic figures, incidence data and experts opinion. A BIA 
model combined the data of official algorithms (standard of treatment approved 
by Ministry of Health of Russian Federation) and guidelines of mPC management, 
as well as local expert opinion and published data on resource use and unit costs 
from published sources. The BIA model stimulates the impact of mHRPC second-
line management with or without Cabazitaxel. Resources to manage first-line 
and second-line treatment included standard chemotherapy, premedication,  
G-CSF prophylaxis, concomitant medications, management of adverse events, 
visits and diagnostics. RESULTS: It was estimated that in the first three years 
following Cabazitaxel introduction in second-line mHRPC patients treatment 
regimen, just 104, 259 and 311 out of 1036 eligible patients with mHRPC 
previously treated with a Docetaxel-containing regimen in first-line would be 
placed on Cabazitaxel therapy respectively. It would imply moderate 
incremental cost of 121.8, 304.6 and 365.5 mln RUB for second-line treatment of 
mHRPC respectively. From the other hand cost for first-line treatment would 
significantly decline due generic erosion of Docetaxel, resulting in following cost 
savings 248.8, 289.0 and 325.2 mln RUB, respectively. As the result the total 
incremental budget increase will be 15,6 and 40,3 mln RUB on second and third 
years of Cabazitaxel introduction, respectively. CONCLUSIONS: Because of small 
size of estimated candidate population the incremental financial budget impact 
on RHNS following the introduction of Cabazitaxel would be very small and 
offset by savings from first-line treatment due to generic erosion of Docetaxel 
price.  
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ESTIMATING THE POTENTIAL BUDGET IMPACT OF ZELBORAF (VEMURAFENIB) 
FOR ADVANCED MELANOMA TREATMENT IN BRAZILIAN PRIVATE HEALTH 
CARE SYSTEM  
Tsuchiya CT, Buschinelli CT, Maximo MFM, Tobaruella FS, Borges LG 
Roche Brazil, São Paulo, Brazil  
OBJECTIVES: Melanoma accounts for less than 5% of skin cancers, but is 
responsible for 90% of skin cancer-related deaths worldwide. According to 
Brazilian Institute of Cancer 2012 statistics, it was estimated 6,230 cases of 
melanoma. BRAF mutations occur in approximately 50% of cases, being 
associated with poorer patient prognosis in advanced melanoma. Historically, 
there have been limited treatment options for advanced melanoma, resulting in 
a critical unmet clinical need for more effective therapies. Vemurafenib is a 
novel targeted therapy, effective for BRAF-V600 mutation-positive unresectable 
or metastatic melanoma treatment, orally administrated and available in 
Brazilian market since 2012. Therefore, the aim of this study was estimate the 
economic impact of vemurafenib reimbursement in Brazilian Private Healthcare 
System Budget. METHODS: Based on an epidemiologic approach, the potential 
number of patients for vemurafenib was estimated. Only the private market was 
considered, accounting for 40% of all patients and only drug costs were 
evaluated. The ex-factory price and labeled dose of 960mg b.i.d. were used. 
Average therapy duration of 6 months was assumed. Costs were reported in 
Brazilian Reais (BRL1.00~USD0.48 Dec. 2012). A total health assistance budget of 
BRL67.9 billion was considered, according to Brazilian National Agency for 
Supplementary Health data from 2012. RESULTS: A total of 756 cases of 
advanced melanoma are expected in 2013 in the private system, corresponding 
potentially to 378 patients harboring BRAF-V600E mutation. Treating all potential 
patients with vemurafenib would yield a total drug cost of BRL59.101.395, 
corresponding to a potential budget impact of 0.087%, considering health 
assistance budget. Cost savings owing to oral administration was not considered. 
CONCLUSIONS: By identifying the patients with BRAF-V600E mutation, therapy 
can be targeted to those who present a higher chance to respond to treatment, 
resulting in a potential low impact of vemurafenib in private health care system 
budget, mainly because of its very selected and specific eligible population.  
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PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY 
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OBJECTIVES: To identify the dominant scheme of adjuvant breast cancer therapy 
(comparing the two chemotherapy regimens - 6FAÑ (6 cycles: 5-Fluorouracil + 
Doxorubicin + Cyclophosphamide) vs 6DAC (6 cycles: Docetaxel + Doxorubicin + 
Cyclophosphamide)). METHODS: Based on the Markov model, the cost of 
treatment for breast cancer was evaluated; an â òî æå âgåìÿ analysis of direct 
and indirect costs was conducted. Direct costs included cost of adjuvant 
chemotherapy (6FAC and 6DAC), medical services, adjuvant endocrine therapy, 
cardiac monitoring, current therapy cost and cost of treatment complications. 
Indirect costs included cost of patient’s disability, maintenance of orphans, GDP 
losses caused by mortality and disability and sick-pay. RESULTS: Based on a 
clinical study BCIRG 001 (Martin M, Mackey J, Pienkowski T) and as an outcome 
of Markov simulation it was determined that the use of 6DAC for adjuvant 
therapy in 10 year horizon of research allows to increase the disease-free 
survival by 6.09%, and overall survival by 5,88% comparing to 6FAC. Use of 6DAC 
instead of 6FAC allows to reduce the number of patients with local relapse, 
regional relapse and metastasis insignificantly as well. In the result of direct 
costs analysis it was determined that for 10-years horizon cost rate for the 
treatment of one patient with breast cancer will be $66,026 for 6DAC and $60,845 
for 6FAC. Direct and indirect costs rate of the breast cancer treatment were 
$84,818 and $85,991 for the 6DAC and 6FAC schemes respectively. 
CONCLUSIONS: It was determined that the scheme of adjuvant therapy that 
includes Docetaxel besides of addition efficiency, allows to reduce the cost rate 
to $1173 in 10 years.  
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OBJECTIVES: Lung cancer (LC) is one of the major health problems due its high 
mortality. The most common type of LC is non-small cell lung cancer (NSCLC), 
which accounts for approximately 80% of all LC cases; approximately 3%-5% of 
these have a gene defect called ALK (anaplastic lymphoma kinase). The aim of 
this study was to evaluate the budgetary impact of adding crizotinib for patients 
with ALK-positive advanced NSCLC in Colombia. METHODS: A budget-impact 
model was developed to evaluate crizotinib from the payer perspective. 
Comparators were: crizotinib (250mg bid), erlotinib (150mg/day), 
bevacizumab/platinum doublet (15mg/kg/Carboplatin AUC6+Paclitaxel 200mg/m2 
per cycle [28 days]), paclitaxel/platinum (Carboplatin AUC6+Paclitaxel 200mg/m2 
per cycle), docetaxel/platinum (Cisplatin 75mg/m2 + Docetaxel 75mg/m2 per 
cycle), pemetrexed/platinum (Carboplatin AUC6+Pemetrexed 500mg/m2 per 
cycle), gemcitabine/platinum (Cisplatin 75mg/m2 day1+Gemcitabine 
2,500mg/m2per cycle). Two scenarios were compared: (1) no tested patients, 
excluding crizotinib (2) all patients tested with FISH (diagnostic test) to identify 
ALK-positive NSCLC patients; it was taken into account a positive match for ALK 
of 4.2% and only 3% receiving crizotinib. Epidemiology and acquisition, 
administration and adverse events costs were estimated from Colombian 
sources, values are expressed in 2012 US$. RESULTS: Considering Colombian 
population >18 years (incident rate of LC 0.018%, proportion NSCLC 87.86% and 
advanced NSCLC 52.29%), it was estimated a cohort of 4768 advanced NSCLC 
patients, overall 1-year costs of treating patients with NSCLC would be 
US$197,929,584 with crizotinib, compared with US$190,725,844 without 
crizotinib. Acquisition costs of crizotinib were offset by reductions in adverse 
events (AE) costs (anemia, anorexia, asthenia, diarrhea, dyspnea, fatigue, 
neutropenia, neutropenic infection, nausea, vomiting, pulmonary events,). 
Administration costs accounted between 37.77%-38.16% of total costs, while AE 
management costs made up 1.19% to 1.27% of total costs. CONCLUSIONS: 
Treating ALK-positive advanced NSCLC patients with crizotinib, leads to a 
decrease in total costs of managing adverse events (US$65,042) and progression 
costs.  
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BUDGET IMPACT MODEL FOR CUTANEOUS T-CELL LYMPHOMA  
Aggarwal S, Topaloglu H 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Develop budget impact model to forecast total cost of treatment for 
cutaneous T-cell lymphoma (CTCL) for U.S. public and private payer. METHODS: 
The clinical efficacy and safety data were obtained from the published pivotal 
study results. Costs of adverse events were estimated based on claims database 
analysis, AHRQ’s HCUP, and CMS Medicare 2009 databases. Drug cost was 
estimated based on 2011 AWP price. Epidemiology data was obtained from NCI-
SEER and CDC databases. A budget impact model was implemented over a period 
of five years, based on a stable population and on different penetration and 
substitution rates of newly approved therapy. Model was developed in excel 
based format. Blinded Model design and outputs were tested with payers and 
KOLs. RESULTS: For rare cancers such as CTCL, the budget impact of treatment 
with targeted cancer therapies is in the range of $460,000-$530,000 per 1 million 
covered lives. The per patient per member (PPPM) budget impact of this 
treatment is 46-53 cents. U.S. payers rated PPPM output as the one of the most 
important relevant outputs of model. CONCLUSIONS: This budget impact model 
shows that new treatments for rare forms of cancer are likely to have minimal 
budget impact on payers. PPPM based outputs are more relevant to payers, than 
per patient treatment costs. However, an emerging concern is the total budget 
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impact of all therapies indicated for ultra-orphan disorders, which might be an 
important consideration for future models.  
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ESTIMATING DEVELOPMENT COST OF AN INTERACTIVE WEBSITE BASED 
CANCER SCREENING PROMOTION PROGRAM  
Chung TH1, Lairson DR1, Smith LG2, Champion VL3 
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OBJECTIVES: The aim of this study is to estimate the development costs of a 
tailored intervention delivered via the interactive web, designed to increase 
cancer screening in women 51 to 75 who are non-adherent to colorectal cancer 
(CRC) and may or may not be adherent to breast cancer screening. METHODS: 
The cost of the intervention development is estimated from a societal 
perspective. Micro costing methods plus vendor contract costs were used to 
estimate the intervention development cost. Staff logs were used to track 
personnel time. Non-personnel costs include all resources used to produce the 
intervention. RESULTS: Development cost of the interactive web based 
intervention is $0.39 million, of which 77% is direct cost. About 98% of the cost 
was incurred in personnel time cost, contract cost and overhead cost. Eighteen 
persons contributed a total of 1610 hours to intervention development. 
CONCLUSIONS: The new web-based disease prevention medium requires 
substantial investment of health promotion and media specialist time. As health 
promotion and disease prevention programs move to the internet, it is important 
to assess development and intervention costs along with program impacts on 
health behaviors and outcomes. The cost of intervention development is 
important for planning future investments in web-based health promotion 
interventions and also relevant to the private sector investment and pricing 
decisions for new health promotion products and services.  
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ADHERENCE TO AND COSTS OF LIFE EXTENDING THERAPIES FOR METASTATIC 
CASTRATE-RESISTANT PROSTATE CANCER  
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OBJECTIVES: Life extending therapies (LETs) for metastatic castrate-resistant 
prostate cancer (mCRPC) increase overall survival. This study examined 
adherence to LETs and concomitant corticosteroids, and health care costs. 
METHODS: A retrospective claims study of commercial and Medicare Advantage 
enrollees with evidence of prostate cancer (ICD-9: 185.xx) between July 1, 2006 – 
June 30, 2011. mCRPC patients were identified based on evidence of LET use: 
docetaxel (DOC), cabazitaxel (CAB), and/or abiraterone acetate (ABI). The index 
date was the first date of chemotherapy. Patients were continuously enrolled for 
6 months before (baseline) and ≥6 months after the index date until December 
31, 2011 or death (follow-up). Adherence was defined as the proportion of days 
covered (PDC). Costs were the sum of health plan- and patient-paid amounts. 
Descriptive statistics summarized PDC and costs during follow-up. RESULTS: A 
total of 1,198 patients had ≥1 LET (DOC: 1,196, CAB: 27, ABI: 109). Mean±SD age 
was 69±9 years. Average PDC for LET was: DOC: 0.91, CAB: 0.88, ABI: 0.96. Half or 
more had a concomitant corticosteroid: DOC: 552, CAB: 17, ABI: 99, with an 
average PDC of: DOC 0.57, CAB 0.62, ABI 0.74. Average±SD cumulative 12-month 
health care costs were $76,550±$82,485. Average±SD per-patient-per-month 
(PPPM) health care costs during LET were higher for patients with a concomitant 
corticosteroid than those without: $9,307±$7,436 versus $5,929±$11,103; p<0.001. 
Patients with high adherence to a concomitant corticosteroid (PDC≥80%) had 
higher average PPPM costs during LET than patients with lower adherence 
(PDC<80%) or without: $9,028±$7,133 versus $7,339±$9,992; p=0.002. 
CONCLUSIONS: mCRPC patients had high adherence to LET but lower adherence 
to indicated concomitant corticosteroid. Average PPPM costs were higher for 
patients with greater adherence to concomitant corticosteroids than patients 
with lower adherence or no use. Multivariate analyses are planned to better 
understand the association between corticosteroid adherence during LET use 
and costs. The database timeframe did not allow for the inclusion of newer 
therapies.  
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RECEIVING TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)  
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients 
aged ≥65 years receiving treatment for mRCC. METHODS: Retrospective study 
using the linked SEER (Surveillance, Epidemiology and End Results) Medicare 
database. Study subjects consisted of all persons in the linked SEER-Medicare 
database, aged ≥65 years, with evidence of newly diagnosed mRCC between 
January 1, 2007 and December 31, 2007. AEs of interest comprised abdominal 
pain, back pain, diarrhea, dyspnea, extremity pain, fatigue/asthenia, hand-foot 
syndrome, hypertension, lymphopenia, nausea/vomiting, neutropenia, and 
proteinuria. Patients receiving care for these AEs were identified using ICD-9-CM 
diagnosis codes on Medicare claims. Costs were examined over a 30-day period, 
beginning with date of first mention of each AE; non-evented patients were 
assigned a “shadow” index date for comparison purposes. We estimated total 
costs over 30 days following the index date for patients with and without AEs, on 
both an unadjusted basis and following adjustment for differences in baseline 
characteristics using a generalized linear model (GLM). RESULTS: Sixty percent of 
patients receiving treatment for mRCC had health care encounters for one or 
more AEs. Those occurring 20% or greater frequency included severe abdominal 
pain, dyspnea, and fatigue/asthenia; 10-20% of patients had encounters for back 
pain, extremity pain, and nausea/vomiting. Mean (SD) total costs of care during 
the 30-day, post-index period were substantially higher among patients with AEs 
($13,944 [$14,529] versus $1,878 [$5,264] for those without these events). 
Adjusting for differences in baseline characteristics, the estimated cost 
difference (95% CI) was $11,454 ($7,909 - $16,319). CONCLUSIONS: Costs of AEs 
associated with treatment of mRCC are high in patients aged ≥65 years. Efforts to 
prevent and/or better manage these events may reduce health care costs.  
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OBJECTIVES: As oral chemotherapy is becoming more prevalent in treating 
cancer patients, the cost difference between oral and conventional intravenous 
(IV) chemotherapy is not clear. The objective of this study was to compare the 
total costs of oral chemotherapy and IV chemotherapy in insured, low- income 
patients with breast cancer or colon cancer using South Carolina (S.C.) Medicaid 
claims data. METHODS: Patients with breast or colon cancer and receiving oral 
chemotherapy (capecitabine and oral cyslophosphamide) or conventional IV 
chemotherapy (5-FU and cyclophosphamide) were identified from S.C. Medicaid 
for years 2006-2009. Total costs, including inpatient, outpatient and prescription 
drugs, for one year follow-up period after initiation of chemotherapy were 
calculated. A multiple linear regression model with log transformation was used 
to examine the association between total costs and chemotherapy (oral vs. IV). 
RESULTS: A total of 1219 patients (857 for breast cancer, 362 for colon cancer) 
were identified from S.C. Medicaid claims data for years 2006-2009. The 
unadjusted annual total costs were $45,535(oral) and $59,498 (IV, p<0.001) for 
breast cancer, and $50,385 (oral) and $56,347 (IV, p=0.274) for colon cancer. Oral 
chemotherapy was associated with 36% and 43% reduction in cost for Medicaid 
breast and colon cancer patients respectively after adjusting for confounders. 
CONCLUSIONS: Total cost savings might be achieved in insured, low- income 
patients receiving oral chemotherapy to treat breast and colon cancers. Further 
studies are needed to link the costs to clinical outcomes and adverse drug events 
associated with chemotherapy.  
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CHARGES ASSOCIATED WITH CHEMOTHERAPY INDUCED NAUSEA AND 
VOMITING IN CANCER PATIENTS INITIATING AND MAINTAINING THERAPY 
WITH A 5-HT3-RA THROUGHOUT CHEMOTHERAPY CYCLES  
Faria C1, Nagl N2, Li X1, Powers A3 
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OBJECTIVES: Chemotherapy induced nausea and vomiting (CINV) has clinical 
and economic implications. Controlling CINV upon chemotherapy initiation is 
important as the likelihood of CINV in future chemotherapy cycles increases if a 
patient experiences CINV in the first/previous chemotherapy cycle. The purpose 
of this study was to evaluate economic implications of 5-HT3-RA selection on 
CINV charges. METHODS: A retrospective analysis was conducted utilizing 
medical and pharmacy claims from 2005-2011 from a commercial (96%) and 
Medicaid (4%) population. Continuously enrolled patients (6 month pre-period, 6 
month post-period) with cancer receiving single-day chemotherapy regimens 
were eligible. Patients had to remain on initial 5-HT3-RA therapy and same level 
of emetic potential of chemotherapy throughout the study. CINV was defined as 
primary/secondary diagnosis of nausea, vomiting, or dehydration based on ICD-9 
codes, or use of rescue antiemetic medication. Charges for CINV were captured 
for an overall random sample of 1,000 for each chemotherapy cycle. A charge per 
patient was calculated and used to calculate an average charge for all patients in 
each 5-HT3-RA cohort based on the percentage of patients in each cycle 
experiencing CINV. Patients without CINV in the previous cycle or who switched 
5-HT3-RA therapy were excluded from subsequent calculations. RESULTS: 
Patients receiving palonosetron had lower rates of CINV across chemotherapy 
cycles compared to ondansetron, granisetron, or dolasetron. Patients receiving 
palonosetron had the lowest charges associated with CINV with a total of 
$300,293 over 6 cycles of chemotherapy. Patients receiving granisetron incurred 
the highest charges at $470,131 over 6 cycles. The use of palonosetron has the 
potential to result in a savings of $126,775 (vs ondansetron) to $169,838 (vs 
granisetron), depending on 5-HT3-RA selection. CONCLUSIONS: Patients 
receiving palonosetron experienced lower CINV-associated charges for each 
cycle of chemotherapy. Selection of 5-HT3-RA has the ability to positively impact 
economic outcomes associated with CINV.  
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COMPARATIVE ANALYSIS OF RADIUM-223 VERSUS PLACEBO IN 
SYMPTOMATIC METASTATIC CASTRATION RESISTANT PROSTATE CANCER 
TREATED WITH BEST STANDARD OF CARE ON SKELETAL-RELATED EVENTS 
OUTCOMES  
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OBJECTIVES: Radium-223 dichloride (Ra-223) is a novel alpha-
radiopharmaceutical, which delayed time to first skeletal-related event (SRE) and 
improved overall survival versus best standard of care (BSoC) in patients with 
symptomatic castration-resistant prostate cancer (mCRPC) with bone 
metastases. This analysis evaluated economic benefits associated with Ra-223. 
METHODS: A Markov model was developed using patient-level data from  
a pivotal trial in which mCRPC patients receiving BSoC were randomized 2:1 to 
